Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 28, 2008 Brian Lawler	Can Encysive Catch the Competition? After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals is finally able to capitalize on its very marketable lead drug, Thelin?
The Motley Fool September 6, 2007 Brian Lawler	Encysive, Please Stop Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant. Investors, take note.
The Motley Fool August 4, 2005 Charly Travers	This One's a Winner Encysive awaits FDA approval, and all signs are positive. Biotech investors, take note.
The Motley Fool March 7, 2007 Brian Lawler	Encysive's Outback Adventures The pharmaceutical gains marketing approval for its lead compound in Australia. Investors, take note.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
The Motley Fool December 17, 2007 Brian Lawler	Is There Value in This Hypertension Fighter? Encysive Pharmaceuticals announces what looks like a far too optimistic 2008 revenue guidance for its lead drug, Thelin. Investors, take note.
The Motley Fool November 5, 2007 Brian Lawler	Encysive in a No-Win Situation Encysive Pharmaceuticals needs help to get its lead drug onto the U.S. market in time to turn its financials around. Investors, take note.
The Motley Fool August 7, 2007 Brian Lawler	Encysive's Congested Sales Failure Encysive Pharmaceuticals releases quarterly results that reveal a company with problems. Its cost structure is way out of line for a drugmaker of its size and potential.
The Motley Fool February 22, 2008 Brian Lawler	The Hypertension Fight Expands News from the pharmaceutical industry regarding hypertension medications: Gilead and Glaxo win E.U. approval for a drug, and Encysive's sellout came just in time.
BusinessWeek October 17, 2005 Gene G. Marcial	Encysive Is Breathing Easy Among biotechs favored by Mark Monane of investment firm Needham is Encysive Pharmaceuticals.
The Motley Fool March 28, 2008 Brian Lawler	Pfizer Gets the Signal to Steal Pfizer's acquisition of Encysive Pharmaceuticals is set for Monday.
The Motley Fool December 11, 2006 Brian Lawler	Another Go for Encysive Drug Trials Sometimes shares of small specialty-pharma stocks rise and fall much more than warranted on every piece of news, and this appears to have happened to Encysive Pharmaceuticals.
The Motley Fool July 25, 2006 Brian Lawler	Strike Two for Encysive The FDA still won't quite give Thelin a thumbs-up. For now, Encysive investors can only sit and wait.
The Motley Fool June 18, 2007 Brian Lawler	The Third Time Isn't the Charm for Encysive The approvable letter for the pulmonary arterial hypertension treatment marks the third time Thelin has failed to get full approval from the FDA. Investors, take note.
The Motley Fool June 2, 2006 Brian Lawler	Encysive Can Breathe Easier The pharmaceutical's crucial Thelin drug gains EU approval. Encysive's next critical hurdle lies here in the U.S. Whatever the FDA's decision, expect more volatility in Encysive shares.
The Motley Fool February 18, 2005 Charly Travers	A Drug to Get Your Blood Pumping Encysive's Thelin combines low risk with high sales potential.
The Motley Fool February 21, 2007 Brian Lawler	Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note.
The Motley Fool June 15, 2007 Brian Lawler	Encysive's Date With Destiny Approaches A decision on the specialty drugmaker's lead drug is imminent. Betting against the FDA is generally not a good idea for investors. Here are statements from Encysive's past press releases about Thelin
The Motley Fool December 29, 2006 Brian Lawler	Third Time's the Charm for Encysive? It seems like every other week we hear about a new delay for Encysive's lead drug Thelin. With shares of Encysive down more than 20% yesterday, investors can only hope that the third time is the charm for Thelin's approval from the FDA.
The Motley Fool September 24, 2007 Brian Lawler	Encysive Hears the Voice of Reason To please the FDA, Encysive Pharmaceuticals announces it is planning an additional phase 3 trial to try and bring its lead drug, Thelin, to market in the United States.
The Motley Fool July 19, 2007 Brian Lawler	Will Encysive's FDA Challenge Fail? The pharmaceutical gets set for a showdown with the FDA. Investors should think long and hard about whether shares of Encysive are worth holding, considering that the likely result of this dispute resolution process won't be positive.
The Motley Fool May 11, 2006 Brian Lawler	Encysive Evasive About Thelin The pharmaceutical stays tight-lipped about FDA approval of its new drug. Investors should keep an eye on Encysive's cash-burn rate in the coming months.
The Motley Fool December 7, 2006 Brian Lawler	The Best Small Cap for 2007: Encysive Pharmaceuticals This little drug maker has the potential for big profit, in both the U.S. and Europe. Investors, take note.
The Motley Fool June 18, 2007 Brian Lawler	Gilead Gets the Payoff Gilead gets marketing approval for one of its drug candidates. Investors, take note.
BusinessWeek July 26, 2004 David Henry	Taking Encysive To Heart Buying into a company that bets heavily on a single new drug is dicey. But sometimes it's a risk worth taking.
The Motley Fool June 26, 2007 Brian Lawler	Changing of the Guard at Encysive Encysive Pharmaceuticals restructures to reduce its cash burn.
The Motley Fool September 26, 2007 Brian Lawler	Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures.
The Motley Fool September 19, 2008 Brian Lawler	FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA.
The Motley Fool January 21, 2009 Brian Orelli	Pharma Foe Speaks Up for Investors Some good ideas for President Obama's new Food and Drug Administration chief that would benefit investors in drug companies.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool March 12, 2007 Brian Lawler	Encysive Sings the Blues The tiny drug developer announces a slower-than-expected launch of its lead drug. Investors, take note.
The Motley Fool January 10, 2011 Brian Orelli	By the Way, We Need to Run Another Trial InterMune has decided to run a new trial to gain U.S. approval on its idiopathic pulmonary fibrosis drug.
The Motley Fool May 14, 2008 Brian Lawler	Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies.
The Motley Fool December 15, 2006 Brian Lawler	Reformatting Encysive Yet another delay from the FDA leaves investors hanging.
The Motley Fool October 19, 2007 Brian Lawler	The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note.
The Motley Fool March 12, 2007	Uncertain Encysive: Fool by Numbers The tiny pharmaceutical released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool December 12, 2005 Stephen D. Simpson	Heavy Breathing for Myogen Positive data from a phase 3 drug study sends shares of this biotech much higher.
The Motley Fool August 2, 2007 Brian Lawler	United Therapeutics Unites R and D The drugmaker quietly beats the market while vying for its share of customers. Investors, take note.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool June 29, 2009 Brian Orelli	Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug.
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool February 16, 2007 Brian Lawler	The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc.
The Motley Fool December 31, 2003 Alyce Lomax	Nothing Decisive About Encysive Analyst initiation boosts the stock during the slow holiday week.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.